Médecine

Paramédical

Autres domaines


S'abonner

Serious infections among a large cohort of subjects with systemically treated psoriasis - 27/12/17

Doi : 10.1016/j.jaad.2017.07.047 
Allison S. Dobry, MD a, b, Charles P. Quesenberry, PhD c, G. Thomas Ray, MBA c, Jamie L. Geier, PhD d, Maryam M. Asgari, MD, MPH a, b, c,
a Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts 
b Department of Population Medicine, Harvard Medical School, Boston, Massachusetts 
c Division of Research, Kaiser Permanente Northern California, Oakland, California 
d Pfizer Inc, New York, New York 

Correspondence to: Maryam M. Asgari, MD, MPH, Department of Dermatology, Massachusetts General Hospital, 50 Staniford St, Suite 270, Boston, MA 02114.Department of DermatologyMassachusetts General Hospital50 Staniford St, Suite 270BostonMA02114

Abstract

Background

Biologic therapy is effective for treatment of moderate-to-severe psoriasis but may be associated with an increased risk for serious infection.

Objective

To estimate the serious infection rate among patients with psoriasis treated with biologic as compared with nonbiologic systemic agents within a community-based health care delivery setting.

Methods

We identified 5889 adult Kaiser Permanente Northern California health plan members with psoriasis who had ever been treated with systemic therapies and calculated the incidence rates and 95% confidence intervals (CIs) for serious infections over 29,717 person-years of follow-up. Adjusted hazard ratios (aHRs) were calculated using Cox regression.

Results

Adjusting for age, sex, race or ethnicity, and comorbidities revealed a significantly increased risk for overall serious infection among patients treated with biologics as compared with those treated with nonbiologics (aHR, 1.31; 95% CI, 1.02-1.68). More specifically, there was a significantly elevated risk for skin and soft tissue infection (aHR, 1.75; 95% CI, 1.19-2.56) and meningitis (aHR, 9.22; 95% CI, 1.77-48.10) during periods of active biologic use.

Limitations

Risk associated with individual drugs was not examined.

Conclusion

We found an increased rate of skin and soft tissue infections among patients with psoriasis treated with biologic agents. There also was a signal suggesting increased risk for meningitis. Clinicians should be aware of these potential adverse events when prescribing biologic agents.

Le texte complet de cet article est disponible en PDF.

Key words : biologics, epidemiology, psoriasis, serious adverse infections, soft tissue infections, TNF-α

Abbreviations used : aHRs, CI, IL, IR, KPNC, SSTI, TNF-α


Plan


 Supported by Pfizer Inc and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant K24 AR069760 to MA).
 Disclosure: In addition to research support from Pfizer Inc, Dr Asgari and Dr Quesenberry have received research support from Valeant Pharmaceuticals and Mr Ray has received research support from Merck & Co, Genentech, and Purdue Pharma. Dr Geier is an employee of Pfizer, Inc. Dr Dobry has no conflicts of interest to declare.
 Reprints not available from the authors.


© 2017  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 77 - N° 5

P. 838-844 - novembre 2017 Retour au numéro
Article précédent Article précédent
  • Oropharyngeal lesions in pityriasis rosea
  • Giulia Ciccarese, Francesco Broccolo, Alfredo Rebora, Aurora Parodi, Francesco Drago
| Article suivant Article suivant
  • Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry
  • David Fiorentino, Vincent Ho, Mark G. Lebwohl, Luiz Leite, Lori Hopkins, Claudia Galindo, Kavitha Goyal, Wayne Langholff, Steven Fakharzadeh, Bhaskar Srivastava, Richard G. Langley

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.